A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and...
Vous n'êtes pas connecté
Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 15/11/2024 07:02
Columbia researchers have engineered probiotic bacteria that educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines that take advantage of bacteria’s natural tumour-targeting properties. These microbial cancer vaccines can be personalised to attack each individual’s primary tumour and metastases, and may even prevent future recurrences. In [...]
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and...
A research team led by Professor Eijiro Miyako at the Graduate School of Advanced Science and Technology, Japan Advanced Institute of Science and...
A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumours such as triple-negative breast cancer has been...
A cancer-targeting antibody that helps the body’s immune cells spot and destroy hard-to-treat tumours such as triple-negative breast cancer has been...
Researchers at The University of Texas MD Anderson Cancer Centre, USA, have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism...
Researchers at The University of Texas MD Anderson Cancer Centre, USA, have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism...
An experimental cancer vaccine developed at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy,...
An experimental cancer vaccine developed at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy,...
Researchers at The University of Texas MD Anderson Cancer Center have found that renal medullary carcinoma (RMC) cells use an adaptive mechanism...
Highlights: LungVax trains the immune system to recognize abnormal lung cells Clinical trials begin in summer